About Sunshine Heart

C-Pulse Device

Board of Directors

The Board of Directors have been involved in regulatory approval and commercialization of devices and treatments of heart failure and heart disease internationally. They also have significant connections with leading global medical device companies including Medtronic, Johnson & Johnson, Boston Scientific, Baxter Healthcare and Edwards Lifesciences.

 

John Erb

Chairman

John Erb has over 35 years of experience in the medical device industry. Mr. Erb has been Chairman and Chief Executive Officer of Cardia Access, Inc., a medical device company focused on novel technologies for pacing the heart since 2007.

From 2001 through 2006, Mr. Erb was Chief Executive Officer of CHF Solutions, Inc., a medical device company focused on the treatment of congestive heart failure. CHF Solutions, Inc. was acquired by Gambro. From 1997 through 2001, Mr. Erb was President and Chief Executive Officer of IntraTherapeutics, Inc., a medical device company involved in the development, manufacturing and distribution of peripheral vascular stents. IntraTherapeutics, Inc. was acquired by Sulzer Medica.

Previously, Mr. Erb was Vice President of Operations for Schneider Worldwide, a division of Pfizer, Inc. Mr. Erb spent 10 years with Johnson & Johnson’s Iolab Division and started his career with American Hospital Supply Corporation.

Mr. Erb serves as Chairman of the Board of Directors for Vascular Solution, Inc., a public NASDAQ company and Chairman of the Board of Directors for Osprey Medical, a public ASX company. Mr. Erb previously served on the Board of Directors of CryoCath Technologies, acquired by Medtronic in 2008 and SenoRx, Inc., acquired by CR Bard in 2010.

Mr. Erb has a bachelor's degree in business administration from California State University, Fullerton.

 

Geoffrey Brooke, MD - Non-executive Member

Geoffrey Brooke, MD

Non-executive Member

Dr. Brooke is managing director of GBS Venture Partners Ltd., which manage A$150 million in early stage venture funds. Previously, he was Managing Director of GBS when it was a part of the Rothschild Group, until he and another partner purchased the business in 2002. Prior to joining Rothschild, Dr. Brooke worked with Johnson & Johnson to co-found MedVest Inc., a US-based early stage venture capital group.

With more than 15 years of venture capital experience, Dr. Brooke has been the founder, lead investor and director of US- and Australian-based healthcare and bioscience companies, many of which have been sold or undertaken IPO’s on the NASDAQ or ASX.

A medical graduate of the University of Melbourne with several years of clinical experience, Dr. Brooke also holds an MBA from IMEDE (now IMD) in Switzerland. He became a Director of Sunshine Heart in 2002.

 


Paul Buckman

Non-Executive Member

Mr. Buckman brings more than three decades of medical industry leadership. Paul is currently president and CEO of SentreHEART, Inc., a Palo Alto, CA company focused on soft tissue closure. Paul has served on the board of SentreHEART for the past six years.  He was previously at Pathway Medical, where he served as chairman of the Board of Directors prior to becoming president and CEO. The company was acquired by Bayer Healthcare in 2011. Prior to that he was at Devax, Inc. where he served as chief executive officer and a board member since December 2006. From August 2004 to December, 2006, Mr. Buckman was president of the Cardiology Division of St. Jude Medical, Inc., a diversified medical products company. Prior to St. Jude Medical, he served as chairman of the Board of Directors and chief executive officer of ev3, LLC, a Minnesota-based medical device company focused on endovascular therapies that Paul founded and developed into an $80 million business. Paul’s 30 years in the medical device industry include 10 years at Scimed Life Systems, Inc. and Boston Scientific Corporation, where he held several executive positions before becoming president of the Cardiology Division in January 2000.

Paul currently serves as a board member for SentreHEART, Inc., Devax, Conventus, and Bio-Star Ventures, and has held posts on the boards of Velocimed, Inc., where he was a co-founder, EndiCor, Inc., Microvena, Inc. and Micro Therapeutics, Inc.

 


Greg Waller

Non-Executive Member

Mr. Waller has over 35 years of financial and management experience with an emphasis in financial management, accounting, treasury and mergers/acquisitions. Greg was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories, from March, 2006 until April of 2011 where he implemented several cost savings initiatives that saved the company several millions of dollars. Previous to that, he had been in retirement except for board positions. Prior, Mr. Waller served as the Chief Financial Officer, Vice President of Finance and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products. At Sybron he was instrumental in a variety of initiatives including being instrumental in the IPO of the company, over 30 company acquisitions worldwide and sales growth from $10 million to over $750 million during his twenty-five year tenure at Sybron. He was the Vice President of European Operations for Kerr (a subsidiary of Sybron) and Vice President and Controller at Ormco (also a subsidiary of Sybron) during his time at Sybron. Mr. Waller has an MBA with a concentration in accounting from California State University, Fullerton.

Greg currently serves as a board member and audit committee chairman for Endologix, Inc. He previously served as board member and audit committee chairman for Alsius, Inc., Biolase, Inc., Cardiogenesis Inc., Clarient, Inc. and SenRx, Inc., all publicly traded companies.

 


Warren S. Watson

Non-Executive Member

Mr. Watson is a medical device executive with over 35 years of med tech experience. Mr. Watson’s career began with Medtronic, Inc. where he served in capacities of increasing responsibility for greater than 30 years. Mr. Watson focused in the Cardiac Rhythm Management, Cardiac Ablation, Heart Failure and Cardiology fields including positions in technical management, clinical and regulatory responsibilities, business development, strategic and marketing responsibilities, and general management. Mr. Watson served as VP of Research and Development for the Cardiac Rhythm Management business for over 8 years and was Chair of the Medtronic Corporate Research and Development Council. Mr. Watson retired from Medtronic with 33 years of service to the Company.

Following his retirement from Medtronic, Mr. Watson has served on multiple medical device, non-med tech and charitable organization Boards:

Executive Chair of the Board of Directors for Cameron Health, Inc. Cameron Health is a California based medical device company developing a subcutaneous implantable defibrillator for patients at risk of sudden cardiac death. He served on the board until Cameron Health was purchased by Boston Scientific, Inc. in June, 2012.

Board of Directors for Cardia Access, Inc. Cardia Access is a Minneapolis based early stage medical device company focused on development of innovative technology for endocardial cardiac leads.

Board of Directors for Cardialen, Inc. Cardialen is a Minneapolis based early stage medical device company developing unique, non-ablative technology for the termination of atrial fibrillation.

Advisor to the Office of Technology Commercialization at the University of Minnesota. He works closely with the Venture Center where he focuses on the launch of new medical device companies based on U of MN. Innovation.

Board of Gillette Children’s Specialty Healthcare in St. Paul, MN. Gillette Children’s is a hospital system treating children with rare and disabling medical conditions.

Board of Directors of Citizen’s Independent Bank of St. Louis Park, Minnesota. Citizen’s Independent Bank is a community based bank serving customers across the Twin Cities with four branch offices and over $300MM in assets.

Mr. Watson is a graduate of the University of Minnesota with undergraduate and graduate degrees in Electrical Engineering. He resides in New Brighton, MN.

 


Jon Salveson

Non-Executive Member

Jon Salveson is the Vice Chairman, Investment Banking and Chairman of the Healthcare Investment Banking Group at Piper Jaffray. Mr. Salveson joined Piper Jaffray in 1993 and became a Managing Director in 1999. He was named the Group Head of Piper Jaffray’s healthcare investment banking group in 2001.

He then was appointed Global Head of Investment Banking and a member of the Executive Committee of Piper Jaffray in 2004. He has served as Vice Chairman of Investment Banking at Piper Jaffray since 2010. Throughout his career at Piper Jaffray, Mr. Salveson’s area of practice has focused on the medical device industry.

Mr. Salveson started his career as a market manager at Bio-Metrics Systems (now part of Surmodics, Inc), an innovator in medical device surface modification, where he gained experience working in cardiology and interventional medicine. Currently, he serves on the Board of Directors at the Minnesota Orchestra since 2007 and CyroLife Inc. since 2012. In addition, he serves on the Board of Regents for St. Olaf College since 2011.

Mr. Salveson received his M.M.M. in finance from the Kellogg Graduate School of Management at Northwestern University and a B.A. in chemistry and religion from St. Olaf College.